Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Recurrent Histiocytic and Dendritic Cell Neoplasm

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Recurrent Histiocytic and Dendritic Cell Neoplasm

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 1 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      4 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT03213665 · Source cited / selected · Scope: narrower

      Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03213678 · Registry condition search · Scope: narrower

      Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATC

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03213704 · Registry condition search · Scope: narrower

      Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03698994 · Registry condition search · Scope: narrower

      Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-recurrent-histiocytic-and-dendritic-cell-neoplasm
        binding id
        ncit-C134172
        source collection
        ncit-concept
        source key
        C134172
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice